Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Artículo en Inglés | MEDLINE | ID: mdl-33252116

RESUMEN

AIM: The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. PATIENTS AND METHODS: Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. RESULTS: 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. CONCLUSION: The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients.


Asunto(s)
Carcinoma de Células Renales , Neoplasias Renales , Anilidas , Carcinoma de Células Renales/tratamiento farmacológico , Carcinoma de Células Renales/patología , República Checa , Humanos , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/patología , Piridinas , Estudios Retrospectivos , Resultado del Tratamiento
2.
Percept Mot Skills ; 123(3): 702-716, 2016 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-27590494

RESUMEN

The Movement Assessment Battery for Children-Second Edition is one of the most frequently used tests for assessment of the fundamental motor skills in children. However, there is the question which sensorimotor functions are really captured by the tasks involved in the test for the preschool (3-6 years) children (age band 1). The aim of the study was to examine the factorial structure of the age band 1 test. Results of the testing by the age band 1 in a sample of three- to- six-year-old children (N = 399; 202 boys, 197 girls) were put to confirmatory factor analysis. The results of the study proved the three-specific factor structure of the age band 1. Thus, within the assessment of a child's overall motor proficiency, the motor competence profile including manual dexterity, aiming and catching, and balance abilities can be identified in three- to six-year-old children.


Asunto(s)
Desarrollo Infantil/fisiología , Destreza Motora/fisiología , Pruebas Neuropsicológicas/normas , Psicometría/instrumentación , Niño , Preescolar , Análisis Factorial , Femenino , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...